KiOmed Pharma
The computed 12-month bankruptcy probability of KiOmed Pharma is 0.4% (very low). The company has been active since 2012 and the Belgian State Gazette contains no insolvency or warning signals. No processed annual-account figures are available; this conclusion rests on registry and State Gazette data only.
| Active | 14 yrs |
| Board | 12 |
| Locations | 2 |
| Publications | 19 |
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
| Fiscal year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | volledig | 02-06-2026 | 2026-00132153 |
| 31-12-2024 | volledig | 20-06-2025 | 2025-00163632 |
| 31-12-2023 | volledig | 05-06-2024 | 2024-00115460 |
| 31-12-2022 | volledig | 09-06-2023 | 2023-00116021 |
| 31-12-2021 | volledig | 22-06-2022 | 2022-20081190 |
| 31-12-2020 | volledig | 23-07-2021 | 2021-38500141 |
| 31-12-2019 | volledig | 10-07-2020 | 2020-30900243 |
| 31-12-2018 | volledig | 25-06-2019 | 2019-23300316 |
| 31-12-2017 | volledig | 20-06-2018 | 2018-21700448 |
| 31-12-2016 | volledig | 06-07-2017 | 2017-27900395 |
-
Clarentis SriDirectorState Gazette act 25121527 (25-09-2025)Current25-09-2025 → present
-
VALOISAdministrateur non statutaireState Gazette act 25321883 (31-03-2025)Current31-03-2025 → present
-
SPARAXIS S.A.DirectorState Gazette act 24133616 (13-09-2024)Current13-09-2024 → present
-
Benoît FellinDirectorState Gazette act 23106635 (16-08-2023)Current16-08-2023 → present
-
Caroline ThielenDirectorState Gazette act 23106635 (16-08-2023)Current16-08-2023 → present
-
François BlondelPrésident exécutif du conseil d'administrationState Gazette act 23106635 (16-08-2023)Current16-08-2023 → present
2 events
- 16-08-2023 Appointed· Président exécutif du conseil d'administration
- 30-05-2016 Resigned· Director
Show 6 more sitting directors
-
Houtaï ChoumaneManaging directorState Gazette act 23106635 (16-08-2023)Current16-08-2023 → present
-
Marie HobeDirectorState Gazette act 23106635 (16-08-2023)Current16-08-2023 → present
-
Chagral Invest SRLLegal entityDirectorState Gazette act 25121527 (25-09-2025)Current01-06-2023 → present
2 events
- 25-09-2025 Appointed· Director
- 01-06-2023 Appointed· Director
-
Samanda S.A.DirectorState Gazette act 23071547 (01-06-2023)Current01-06-2023 → present
-
Dr Pierre RigauxAdministrateur indépendantState Gazette act 20118180 (09-10-2020)Current09-10-2020 → present
-
Marc NoletDirectorState Gazette act 23106635 (16-08-2023)Current10-03-2020 → present
3 events
- 16-08-2023 Appointed· Director
- 10-03-2020 Resigned· Director
- 10-03-2020 Appointed· Director
Historic, not recently confirmed (5)
-
Marc NOLET de BRAUWERE van STEELANDDirectorState Gazette act 16093242 (06-07-2016)Not recently confirmedlast confirmed in an act from 2016
-
INNODE SALegal entityDirectorState Gazette act 16073900 (30-05-2016)Not recently confirmedlast confirmed in an act from 2016
-
KiOmed PharmaCommisState Gazette act 15176734 (18-12-2015)Not recently confirmedlast confirmed in an act from 2015
-
Monsieur Philippe PireAuditorState Gazette act 15176734 (18-12-2015)Not recently confirmedlast confirmed in an act from 2015
-
S.C.R.L. ERNST & YOUNG REVISEURS D'ENTREPRISEAuditorState Gazette act 15176734 (18-12-2015)Not recently confirmedlast confirmed in an act from 2015
Permanent representatives (4)
-
Caroline ThielenReprésentant permanentState Gazette act 24133616 (13-09-2024)Permanent representative22-09-2021 → present
2 events
- 13-09-2024 Appointed· Représentant permanent
- 22-09-2021 Appointed· Representant permanent
-
Benoit FellinReprésentant permanentState Gazette act 20037976 (10-03-2020)Permanent representative10-03-2020 → present
-
Françoise LeblancReprésentant permanentState Gazette act 20037976 (10-03-2020)Permanent representative- → 10-03-2020
-
Géry LefebvreRepresentant permanentState Gazette act 21113286 (22-09-2021)Permanent representative- → 22-09-2021
Former directors (3)
-
SPARAXISDirectorState Gazette act 25321883 (31-03-2025)Former- → 31-03-2025
-
Flexximum R&D srlLegal entityDirectorState Gazette act 20118180 (09-10-2020)Former- → 09-10-2020
-
Géry LEFEBVREDirectorState Gazette act 16093242 (06-07-2016)Former06-07-2016 → present
| Statutory auditor | IRE/IBR number | Tenure |
|---|---|---|
| EYCurrent Commissaire aux comptes |
- | 22-09-2021 → present |
Show 3 earlier auditors
| Ernst & Young Commissaire aux comptes succeeded by EY in 2021 |
- | 10-03-2020 → 22-09-2021 |
| EY Réviseurs d'Entreprises SRL Commissaire |
- | - → 13-09-2024 |
| Marie-Laure Moreau Commissaire succeeded by Ernst & Young in 2020 |
- | 25-08-2017 → 10-03-2020 |
| NACE primary | Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied(72109) |
| Legal form | Public limited company(014) |
| Incorporation | 04-06-2012 |
| Status | Active |
| Postal code | 4041 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 62042B0366/00B003 | Wallonia | 1.9 ha | - | - |
| 62071B0791/00G004 | Wallonia | 4,437 m² | 1 · 850 m² | 7.2 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
We know of 23 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
25-09-2025 2 directors appointed
- Chagral Invest SRL, Bestuurder
- Clarentis Sri, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Clarentis Sri",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}31-03-2025 Capital increase of €6,046,834.90 to €14,726,836.31
- €8.680.001,41 → €14.726.836,31
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 14726836.31,
"delta_eur": 6046834.9,
"before_eur": 8680001.41,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KiOmed Pharma"
}
}16-01-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}13-09-2024 2 directors appointed, 1 resigning
- SPARAXIS S.A., Bestuurder
- Caroline Thielen, Représentant permanent
- EY Réviseurs d'Entreprises SRL, Commissaire
Technical details
{
"events": [
{
"kind": "director_out",
"role": "commissaire",
"person": {
"rrn": null,
"name": "EY R\u00E9viseurs d\u0027Entreprises SRL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "SPARAXIS S.A.",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma DIVISION LIEGE"
}
}16-08-2023 6 directors appointed
- François Blondel, Président exécutif du conseil d'administration
- Houtaï Choumane, Gedelegeerd bestuurder
- Caroline Thielen, Bestuurder
- Benoît Fellin, Bestuurder
- Marc Nolet, Bestuurder
- Marie Hobe, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "Pr\u00E9sident ex\u00E9cutif du Conseil d\u0027administration",
"person": {
"rrn": null,
"name": "Fran\u00E7ois Blondel",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Houta\u00EF Choumane",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Beno\u00EEt Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marie Hobe",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}01-06-2023 2 directors appointed
- Chagral Invest Srl, Bestuurder
- Samanda S.A., Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Chagral Invest Srl",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Samanda S.A.",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}03-01-2022 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": null,
"notary": {
"name": "Ariane DENIS",
"firm_city": null,
"firm_name": "Yves Godin \u0026 Ariane Denis, Notaires Associ\u00E9s SRL",
"office_city": "Li\u00E8ge",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2022-01-03",
"filing_date": "2021-12-30",
"act_kind_objet": "CAPITAL, ACTIONS, DIVERS, STATUTS (TRADUCTION,"
},
"decision": {
"body": "bijzondere_algemene_vergadering",
"act_date": "2021-12-22",
"unanimous": null
},
"conversion": {
"effective_date": null,
"jurisdiction_to": "BE",
"legal_form_after": "Soci\u00E9t\u00E9 anonyme",
"jurisdiction_from": "BE",
"legal_form_before": "Soci\u00E9t\u00E9 anonyme"
},
"detected_kind": "other",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0846.318.862",
"name": "KIOMED PHARMA",
"role": "other",
"address": "Rue Haute Claire 4, 4041 Herstal",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"7:180",
"7:187",
"7:188",
"39, \u00A71"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La soci\u00E9t\u00E9 a divis\u00E9 ses actions existantes par cent, augmentant ainsi le nombre total d\u0027actions de 89.725 \u00E0 8.972.500. Elle a \u00E9galement \u00E9mis 635.000 nouveaux droits de souscription (\u00AB Warrants SOP 2021 \u00BB) pour financer une future augmentation de capital sous condition suspensive.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Ariane DENIS",
"org_rep_person_name": null
},
"summary_narrative": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de KiOmed Pharma, tenue le 22 d\u00E9cembre 2021, a d\u00E9cid\u00E9 de diviser chaque action existante par cent, portant le capital \u00E0 8.972.500 actions sans valeur nominale. Elle a \u00E9galement \u00E9mis 635.000 droits de souscription (\u00AB Warrants SOP 2021 \u00BB) et a approuv\u00E9 une augmentation de capital conditionnelle \u00E0 l\u0027exercice de ces droits. Les statuts ont \u00E9t\u00E9 modifi\u00E9s pour refl\u00E9ter ces changements, notamment en ajustant le montant du capital \u00E0 5.350.528,90 \u20AC.",
"co_filed_documents": [
"exp\u00E9dition du proc\u00E8s-verbal du 22 d\u00E9cembre 2021",
"les procurations et rapports sp\u00E9ciaux",
"la coordination des statuts"
],
"detected_real_type": "other",
"referenced_correction": null,
"should_reroute_to_category": "capital_shares"
}22-09-2021 2 directors appointed, 1 resigning
- Caroline Thielen, Representant permanent
- EY, Commissaire aux comptes
- Géry Lefebvre, Representant permanent
Technical details
{
"events": [
{
"kind": "director_in",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "Caroline Thielen",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "representant permanent",
"person": {
"rrn": null,
"name": "G\u00E9ry Lefebvre",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "EY",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}09-07-2021 Capital increase of €174,000 to €5,350,528.90
- €5.176.528,90 → €5.350.528,90
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5350528.9,
"delta_eur": 174000.0,
"before_eur": 5176528.9,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}09-10-2020 1 director appointed, 1 resigning
- Dr Pierre Rigaux, Administrateur indépendant
- Flexximum R&D srl, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur ind\u00E9pendant",
"person": {
"rrn": null,
"name": "Dr Pierre Rigaux",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Flexximum R\u0026D srl",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}10-03-2020 3 directors appointed, 2 resigning
- Marc Nolet, Bestuurder
- Benoit Fellin, Représentant permanent
- Ernst & Young, Commissaire aux comptes
- Marc Nolet, Bestuurder
- Françoise Leblanc, Représentant permanent
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Marc Nolet",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Benoit Fellin",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "repr\u00E9sentant permanent",
"person": {
"rrn": null,
"name": "Fran\u00E7oise Leblanc",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "commissaire aux comptes",
"person": {
"rrn": null,
"name": "Ernst \u0026 Young",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "Kiomed Pharma"
}
}07-08-2019 Capital increase of €985,422.07 to €5,176,528.90
- €4.191.106,83 → €5.176.528,90
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 5176528.9,
"delta_eur": 985422.0700000003,
"before_eur": 4191106.83,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}28-05-2019 Capital decrease of €4,313,637.52 to €4,191,106.83
- €8.504.744,35 → €4.191.106,83
Technical details
{
"events": [
{
"kind": "capital_decrease",
"after_eur": 4191106.83,
"delta_eur": -4313637.52,
"before_eur": 8504744.35,
"contribution_type": null
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}20-05-2019 Capital increase of €120 to €8,504,744.35
- €8.504.624,35 → €8.504.744,35
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 8504744.35,
"delta_eur": 120.0,
"before_eur": 8504624.35,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}10-12-2018 Transaction in capital or shares
Technical details
{
"events": [],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
}
}25-08-2017 Marie-Laure Moreau appointed as commissaire
- Marie-Laure Moreau, Commissaire
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commissaire",
"person": {
"rrn": null,
"name": "Marie-Laure Moreau",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}06-07-2016 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOMED PHARMA"
},
"legal_form_change": {
"new": "soci\u00E9t\u00E9 anonyme",
"old": "soci\u00E9t\u00E9 anonyme",
"changed": false
}
}30-05-2016 1 director appointed, 1 resigning
- INNODE SA, Bestuurder
- François BLONDEL, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Fran\u00E7ois BLONDEL",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "INNODE SA",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "KIOmed Pharma"
}
}18-12-2015 3 directors appointed
- KiOmed Pharma, Commis
- S.C.R.L. ERNST & YOUNG REVISEURS D'ENTREPRISE, Auditor
- Monsieur Philippe Pire, Auditor
Technical details
{
"events": [
{
"kind": "director_in",
"role": "commis",
"person": {
"rrn": null,
"name": "KiOmed Pharma",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "S.C.R.L. ERNST \u0026 YOUNG REVISEURS D\u0027ENTREPRISE",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Monsieur Philippe Pire",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0846.318.862",
"name_full": "SYNOLYNE PHARMA"
}
}| Legal nameFR | KiOmed Pharma |